Form 4: Erasca CFO and CBO, David M. Chacko, Reports Stock Option Grant

David M. Chacko, CFO and CBO of Erasca, Inc., reports the acquisition of stock options.

Summary

• On June 20, 2024, David M. Chacko, the CFO and CBO of Erasca, Inc., acquired stock options for 278,812 shares of common stock at an exercise price of $2.03.
• The options vest monthly, with 1/48th of the shares vesting each month starting on June 20, 2024, contingent upon continuous service to Erasca.
• Following the transaction, Chacko directly owns derivative securities for 278,812 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for executives. There are no immediate negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule encourages long-term commitment to the company's success.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules, such as the monthly vesting described in the document, are typical to ensure long-term commitment from the executive.
• The size of the grant (278,812 shares) would need to be compared to grants given to executives in comparable roles at similar-sized biotech companies to assess its relative value.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders, but it also incentivizes the executive to increase shareholder value.

Key Dates